Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DME HOME
ChiCTR2400090425Phase 4Not yet recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Oct 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of aflibercept in diabetic macular edema (DME) (2 arms), sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Mean change in best-corrected visual acuity at 96 weeks. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2400090425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090425.